A retrospective chart review comparing 30-day postoperative infectious complication rate among vedolizumab-treated Crohn's disease patients and those who had received TNFα inhibitors or no biologic therapy.

Trial Profile

A retrospective chart review comparing 30-day postoperative infectious complication rate among vedolizumab-treated Crohn's disease patients and those who had received TNFα inhibitors or no biologic therapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Jan 2018

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Jan 2018 New trial record
    • 18 Dec 2017 Results published in the Alimentary Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top